GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (BSP:U2TH34) » Definitions » Other Income (Expense)

United Therapeutics (BSP:U2TH34) Other Income (Expense) : R$-318 Mil (TTM As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is United Therapeutics Other Income (Expense)?

United Therapeutics's other income expense for the United Therapeutics's pretax income for the three months ended in Sep. 2024 was R$-328 Mil. Its other income expense for the trailing twelve months (TTM) ended in Sep. 2024 was R$-318 Mil.

United Therapeutics Other Income (Expense) Historical Data

The historical data trend for United Therapeutics's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Other Income (Expense) Chart

United Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 92.76 206.82 225.63 -219.78 -68.60

United Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.20 -2.94 8.96 4.31 -328.39

United Therapeutics Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-318 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics  (BSP:U2TH34) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

United Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (BSP:U2TH34) » Definitions » Other Income (Expense)
Comparable Companies
MRNA SMMT INCY INSM BMRN BGNE RPRX TECH PCVX SRPT VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 OCSE:GMAB
Traded in Other Exchanges
UTHR:USA UTH:Germany UTH:Germany
Address
1000 Spring Street, Silver Spring, MD, USA, 20910
Website
https://www.unither.com
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

United Therapeutics Headlines

No Headlines